Post-essential Thrombocythemia Myelofibrosis clinical trials at UCSD

1 in progress, 0 open to eligible people

Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Sorry, in progress, not accepting new patients
A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
La Jolla, California and other locations

Last updated: April 17, 2024

Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)